2. Search Result
Search Result
Results for "

Symmetrical Dimethylarginine

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101410S
    SDMA-d6

    Symmetric Dimethylarginine-d6; NG,NG'-Dimethyl-L-arginine-d6

    		 Endogenous Metabolite Inflammation/Immunology
    SDMA-d6 is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity .
    SDMA-d6
  • HY-101410
    SDMA
    1 Publications Verification

    Symmetric Dimethylarginine; NG,NG'-Dimethyl-L-arginine

    		 Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
    SDMA
  • HY-168263
    PRMT5-IN-45

    		Histone Methyltransferase Apoptosis Cancer
    PRMT5-IN-45 (compound 36) is a potent and selective PRMT5 inhibitor with an IC50 of 3 nM. PRMT5-IN-45 potently reduces the level of symmetric dimethylarginines (sDMA) and inhibits the proliferation of MOLM-13 cell lines by inducing apoptosis and cell cycle arrest .
    PRMT5-IN-45
  • HY-101410R
    SDMA (Standard)

    Symmetric Dimethylarginine (Standard); NG,NG'-Dimethyl-L-arginine (Standard)

    		 Reference Standards Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA (Standard) is the analytical standard of SDMA. This product is intended for research and analytical applications. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
    SDMA (Standard)
  • HY-178028
    PRMT5-IN-53

    		Histone Methyltransferase Cancer
    PRMT5-IN-53 is a gut-restricted and orally active PRMT5 inhibitor with pIC50s of ≥ 9.7 against hPRMT5 and mPRMT5. PRMT5-IN-53 binds to the PRMT5:MEP50 complex with a KD of 11.3 pM. PRMT5-IN-53 effectively inhibits PRMT5 locally in the intestines of mice, significantly reducing the number and area of polyps, while avoiding systemic hematological toxicity (such as anemia, neutropenia). PRMT5-IN-53 can be used for the study of colorectal cancer especially for familial adenomatous polyposis (FAP) .
    PRMT5-IN-53

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: